ImmuPharma plc (LON:IMM – Get Free Report) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 5.38 and traded as low as GBX 3.80. ImmuPharma shares last traded at GBX 4, with a volume of 1,375,219 shares.
ImmuPharma Stock Up 7.5%
The company has a 50-day moving average of GBX 4.21 and a 200 day moving average of GBX 5.38. The firm has a market capitalization of £26.83 million, a PE ratio of -11.62 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last announced its quarterly earnings data on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a negative return on equity of 353.21% and a net margin of 3,519.56%. As a group, equities analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
